PRAME/ PD-L1 dual-targeting cancer vaccine / CK Life Sci - LARVOL DELTA

PDL1-PRAME dual antigen cancer vaccine inhibits melanoma growth in syngeneic mouse model and induces antigen-specific immune responses (AACR 2025) - "Our study highlighted the prospect of developing the PDL1-PRAME dual antigen cancer vaccine for cancer immunotherapy. The vaccine efficacy is being further optimized in terms of its protein structure, adjuvant formulation, and administration route for potential clinical testing."

IO biomarker • Preclinical • Hepatocellular Cancer • Melanoma • Oncology • Solid Tumor • PD-L1 • PRAME

CK Life Sciences’ Investigational Cancer Vaccines Deliver Promising Results - New Preclinical Study Data to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (ACCESSWIRE) - "In recent years, CK Life Sciences has regularly participated at the AACR Annual Meeting. The 2025 Annual Meeting will be held from 25-30 April. At the event, CK Life Sciences will exhibit posters highlighting data from preclinical studies of investigational cancer vaccines programs targeting (i) PRAME (Preferentially Expressed Antigen in Melanoma), (ii) PD-L1 (programmed cell death ligand 1), (iii) B7-H3 (B7 homolog 3) and (iv) Claudin 6 proteins, respectively....In addition, CK Life Sciences will be co-presenting with our research collaborator two posters showcasing our Artificial Intelligence (AI)-empowered platform for designing cancer vaccines."

Preclinical • Colon Cancer • Melanoma • Pancreatic Cancer

CK Life Sciences Presenting Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-targeting PRAME and PD-L1, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting (Yahoo Finance) - "CK Life Sciences Int'l...is presenting preclinical data for its investigational dual-antigen cancer vaccines, co-targeting PRAME (preferentially expressed antigen in melanoma) and PD-L1 (programmed death-ligand 1), on November 4 at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California, USA...In this preclinical study, we investigated whether dual-antigen cancer vaccines co-targeting PRAME and PD-L1 could suppress tumour growth in both prophylactic and therapeutic syngeneic mouse hepatocellular carcinoma (HCC) models....All mice experienced a recoverable body weight loss without any abnormal behavior or reduction of activity after vaccination."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor